Program
florensocatib
Also written as “HSK31858, tablet”, “HSK31858” and “HSK31858 tablets”.
Its studies are mostly in Bronchiectasis · Asthma, led by 2 companies.
Drug pageFlorensocatib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Groupits history only | 1310 open or running | phase 3since Sep 23, 2024 | Aug 16, 2021 | Nov 2026phase 1 · NCT07915024 |
| Chiesi Farmaceutici | 33 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | Dec 9, 2026phase 1 · NCT07683793 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chiesi Farmaceutici only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 13, 2025Named florensocatibINNProposed as its International Nonproprietary Name in WHO's List 132 · before, HSK31858, CHF10196
- Apr 27, 2026First study: phase 3 study in BronchiectasisFirst studyNCT07577804 · 904 planned
- Jun 26, 2026Phase 1 study in Healthy VolunteersNCT07683793 · 18 planned · United Kingdom
- Jul 23, 2026Phase 1 study in Healthy Male VolunteersNCT07744386 · 24 planned · United Kingdom
Ahead
- Dec 9, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07683793
- Dec 15, 2028Primary completion: phase 1 study in Healthy Male VolunteersNCT07744386
- Apr 2030Primary completion: phase 3 study in BronchiectasisNCT07577804
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Chiesi Farmaceutici leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07744386Healthy Male Volunteers · United Kingdom | 1 | Not yet recruiting | Dec 15, 2028 | 24 |
| NCT07683793Healthy Volunteers · United Kingdom | 1 | Not yet recruiting | Dec 9, 2026 | 18 |
| NCT07577804Bronchiectasis | 3 | Not yet recruiting | Apr 2030 | 904 |
How it is read
Names in the registry
- “HSK31858, tablet”, 4 entries
- “HSK31858”, 3 entries
- “HSK31858 tablets”, 2 entries
- “CHF10196”, 2 entries
- “HSK31858 tablet”, 1 entry
Conditions, from the studies’ own filings
- Bronchiectasis, 8 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.